Literature DB >> 20176436

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status.

Victoria C Hodgkinson1, Gina L Eagle, Philip J Drew, Michael J Lind, Lynn Cawkwell.   

Abstract

This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (shotgun and quantitative) mass spectrometry approaches are discussed. Non-mass spectrometry approaches including antibody microarray platforms are described as complementary proteomic strategies. Methods for technical confirmation and clinical validation of putative biomarkers are presented. Use of this proteomic toolbox in the quest for biomarkers of chemotherapy resistance in breast cancer is reviewed. Technical aspects of sample selection, acquisition, storage and analysis are discussed and putative biomarkers identified through proteomic approaches are presented. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20176436     DOI： 10.1016/j.canlet.2010.01.036

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  12 in total

1.  PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS.

Authors:  Matthew P Stokes; Charles L Farnsworth; Albrecht Moritz; Jeffrey C Silva; Xiaoying Jia; Kimberly A Lee; Ailan Guo; Roberto D Polakiewicz; Michael J Comb
Journal:  Mol Cell Proteomics       Date:  2012-02-09       Impact factor: 5.911

2.  Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis.

Authors:  Noriyoshi Miura; Nobuaki Takemori; Tadahiko Kikugawa; Nozomu Tanji; Shigeki Higashiyama; Masayoshi Yokoyama
Journal:  Mol Oncol       Date:  2012-01-04       Impact factor: 6.603

3.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

Review 4.  Current status of methods to assess cancer drug resistance.

Authors:  Theodor H Lippert; Hans-Jörg Ruoff; Manfred Volm
Journal:  Int J Med Sci       Date:  2011-03-23       Impact factor: 3.738

5.  Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.

Authors:  Ling Yao; Yan Zhang; Keying Chen; Xiaofang Hu; Lisa X Xu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

Review 6.  The application of SELDI-TOF-MS in clinical diagnosis of cancers.

Authors:  Chibo Liu
Journal:  J Biomed Biotechnol       Date:  2011-05-23

7.  Complementary PTM Profiling of Drug Response in Human Gastric Carcinoma by Immunoaffinity and IMAC Methods with Total Proteome Analysis.

Authors:  Matthew P Stokes; Charles L Farnsworth; Hongbo Gu; Xiaoying Jia; Camilla R Worsfold; Vicky Yang; Jian Min Ren; Kimberly A Lee; Jeffrey C Silva
Journal:  Proteomes       Date:  2015-08-07

8.  Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma.

Authors:  Zhiwei Qiao; Kumiko Shiozawa; Tadashi Kondo
Journal:  Oncotarget       Date:  2017-11-28

9.  Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

Authors:  Verena Paulitschke; Verena Haudek-Prinz; Johannes Griss; Walter Berger; Thomas Mohr; Hubert Pehamberger; Rainer Kunstfeld; Christopher Gerner
Journal:  J Proteome Res       Date:  2013-06-19       Impact factor: 4.466

Review 10.  Advances in the proteomic discovery of novel therapeutic targets in cancer.

Authors:  Shanchun Guo; Jin Zou; Guangdi Wang
Journal:  Drug Des Devel Ther       Date:  2013-10-24       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.